When you buy through links on our articles, Future and its syndication partners may earn a commission. MRNA technology was thrust into the limelight during the COVID-19 pandemic, but had been in ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

When the Pfizer-BioNTech COVID-19 vaccine was authorized for emergency use by the Food and Drug Administration (FDA) in December 2020, President Donald Trump referred to it as a "medical miracle." ...

A new study has found that receiving messenger RNA-based COVID-19 vaccines such as those from Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) could boost the survival rates of ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

Many New Yorkers planning to use a vaccine to protect themselves and their children from COVID-19 in 2025 now face an increasingly uncertain path to getting the shots. That warning from some doctors ...